Halozyme Therapeutics Inc (HALO)

[biotechinvestor1]

Halozyme’s Chairwomen of the board, Connie L. Matsui, and Michael J. LaBarre, Halo’s Chief Scientific Officer, are former longtime Biogen executives.

The recent run up is in anticipation of a deal with Biogen for their IV Alzheimer’s block buster which will make Darzelex look small potatoes in terms of royalties to halo.

Today, Evercore ISI Group Initiates Coverage On Halozyme Therapeutics with Outperform Rating. Normally, the price runs up before a positive rating and fades shortly after. If halo stays high or has further gains, it’s likely due to anticipation of new deal with Biogen.